Department of Physiology, University of Auckland, Auckland, New Zealand.
Department of Medicine, University of Auckland and Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand.
Am J Physiol Regul Integr Comp Physiol. 2021 Mar 1;320(3):R203-R212. doi: 10.1152/ajpregu.00246.2020. Epub 2020 Nov 18.
Activation of the carotid body (CB) using intracarotid potassium cyanide (KCN) injection increases coronary blood flow (CoBF). This increase in CoBF is considered to be mediated by co-activation of both the sympathetic and parasympathetic nerves to the heart. However, whether cardiac sympathetic nerve activity (cardiac SNA) actually increases during CB activation has not been determined previously. We hypothesized that activation of the CB would increase directly recorded cardiac SNA, which would cause coronary vasodilatation. Experiments were conducted in conscious sheep implanted with electrodes to record cardiac SNA and diaphragmatic electromyography (dEMG), flow probes to record CoBF and cardiac output, and a catheter to record arterial pressure. Intracarotid KCN injection was used to activate the CB. To eliminate the contribution of metabolic demand on coronary flow, the heart was paced at a constant rate during CB chemoreflex stimulation. Intracarotid KCN injection resulted in a significant increase in directly recorded cardiac SNA frequency (from 24 ± 2 to 40 ± 4 bursts/min; < 0.05) as well as a dose-dependent increase in mean arterial pressure (79 ± 15 to 88 ± 14 mmHg; < 0.01) and CoBF (75 ± 37 vs. 86 ± 42 mL/min; < 0.05). The increase in CoBF and coronary vascular conductance to intracarotid KCN injection was abolished after propranolol infusion, suggesting that the increased cardiac SNA mediates coronary vasodilatation. The pressor response to activation of the CB was abolished by pretreatment with intravenous atropine, but there was no change in the coronary flow response. Our results indicate that CB activation increases directly recorded cardiac SNA, which mediates vasodilatation of the coronary vasculature.
用颈动脉体内注射氰化钾(KCN)激活颈动脉体可增加冠脉血流量(CoBF)。这种 CoBF 的增加被认为是通过心脏交感神经和副交感神经的共同激活来介导的。然而,颈动脉体激活期间心脏交感神经活动(cardiac SNA)是否实际上增加尚未确定。我们假设激活颈动脉体会直接增加记录到的心脏 SNA,从而引起冠脉血管舒张。实验在植入电极以记录心脏 SNA 和膈肌肌电图(dEMG)、流量探头以记录 CoBF 和心输出量以及导管以记录动脉血压的清醒绵羊中进行。用颈动脉内 KCN 注射激活颈动脉体。为了消除代谢需求对冠脉流量的贡献,在颈动脉体化学反射刺激期间心脏以恒定速率起搏。颈动脉内 KCN 注射导致直接记录到的心脏 SNA 频率显著增加(从 24±2 增加到 40±4 次/分钟; <0.05),平均动脉压(从 79±15 增加到 88±14mmHg; <0.01)和 CoBF(从 75±37 增加到 86±42mL/min; <0.05)呈剂量依赖性增加。普萘洛尔输注后,KCN 注射引起的 CoBF 增加和冠脉血管传导率被消除,这表明增加的心脏 SNA 介导了冠脉血管舒张。静脉注射阿托品预处理消除了对颈动脉体激活的升压反应,但冠脉血流反应没有变化。我们的结果表明,颈动脉体激活增加了直接记录到的心脏 SNA,后者介导了冠脉血管的舒张。